Real World Evaluation of Teclistamab: A Focus on Infections in Patients With Relapsed Refractory Multiple Myeloma (RRMM)

被引：0
|
作者：
Asoori, Sireesha [1 ]
Martin, Thomas [1 ]
Wolf, Jeffrey [1 ]
Chung, Alfred [1 ]
Arora, Shagun [1 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
CT; teclistamab; relapsed refractory multiple myeloma; infections;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT-630
引用
收藏
页码：S536 / S537
页数：2
相关论文
共 50 条
  • [31] Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
    Jagannath, Sundar
    Lee, Hans C.
    Richter, Joshua Ryan
    Zonder, Jeffrey A.
    Hoffman, James E.
    Zhou, Zheng-Yi
    Horton, Viviana Garcia
    Fillbrunn, Mirko
    Wang, Hongjue
    Mattera, Matthew
    Ma, Qiufei
    Inocencio, Timothy J.
    Xu, Yingxin
    Bergrath, Evelien
    Harnett, James
    Roccia, Tito
    Kroog, Glenn Scott
    Rodriguez-Lorenc, Karen
    Houvras, Yariv
    Bumma, Naresh
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Mezagitamab Induces Immunomodulatory Effect in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Abadier, Michael
    Estevam, Jose
    Berg, Deborah
    Fedyk, Eric Robert
    [J]. BLOOD, 2020, 136
  • [33] POMALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PREVIOUSLY TREATED WITH LENALIDOMIDE
    Gomez, Hernando Marta
    Gironella, Merce
    Abella, Eugenia
    Cabezudo, Elena
    Motllo, Cristina
    Garcia, Antoni
    Sarra, Josep
    Mostacedo, Silvia
    Granell, Miquel
    Rosinol, Laura
    [J]. HAEMATOLOGICA, 2020, 105 : 13 - 14
  • [34] Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Ailawadhi, Sikander
    Stiff, Patrick J.
    Ibrahim, Emad
    Vallurupalli, Anusha
    Cull, Elizabeth H.
    Green, Damian J.
    Oliver, Kate
    Longcor, Jarrod
    [J]. BLOOD, 2019, 134
  • [35] Treatment patterns among patients with relapsed/refractory multiple myeloma (RRMM) in Taiwan
    Huang, Jeffrey Shang-Yi
    Wang, Ming-Chung
    Yeh, Su-Peng
    Chen, Tsai-Yun
    Teng, Chieh-Lin Jerry
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S188 - S189
  • [36] Cost Offsets in the Treatment Journeys of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Ailawadhi, Sikander
    DerSarkissian, Maral
    Duh, Mei Sheng
    Lafeuille, Marie-Helene
    Posner, George
    Ralston, Stephen
    Zagadailov, Erin
    Ba-Mancini, Abbie
    Rifkin, Robert M.
    [J]. BLOOD, 2017, 130
  • [37] Real-World Outcomes with Panobinostat in Patients with Relapsed/Refractory Multiple Myeloma
    Biran, Noa
    Vesole, David H.
    Zhang, Shijia
    Richter, Joshua R.
    Kuo, Yen-Hong
    Schmidt, Linda
    McBride, Laura
    Anand, Palka
    Ivanovski, Kristin
    Pierre, Amy
    Kumka, Susan
    Cuccurullo, Carmela
    Siegel, David S.
    [J]. BLOOD, 2016, 128 (22)
  • [38] Real-world Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): IONA-MM First Interim Analysis
    Thomas, Martin
    Meral, Beksac
    Michele, Cavo
    Wolfgang, Knauf
    Nobuhiro, Tsukuda
    Christina, Tekle
    Zhenming, Zhao
    Manasanch, Elisabet E.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S27 - S27
  • [39] CLINICAL AND TREATMENT CHARACTERISTICS OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN EUROPE
    Oriol, A.
    Steinmetz, T.
    Patel, V
    Kutikova, L.
    Schmidt, N.
    Hennies, N.
    Thiess, A.
    Kostev, K.
    Leleu, X.
    [J]. VALUE IN HEALTH, 2019, 22 : S497 - S498
  • [40] REAL WORLD USE OF IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED AND RELAPSED REFRACTORY MULTIPLE MYELOMA
    Ziff, M.
    Cheesman, S.
    Kyriakou, C.
    Mehta, A.
    Papanikolaou, X.
    Rabin, N.
    Wechalekar, A.
    Yong, K.
    Popat, R.
    [J]. HAEMATOLOGICA, 2017, 102 : 786 - 787
12345